Evidence map›Paper›PMID 24691609›Full record

ReviewJAMA2014

Screening mammography in older women: a review.

Louise C Walter, Mara A Schonberg

Open access · greenAbstract readCase ReportsReview
In one paragraph

Review in JAMA, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 7 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 7 syntheses or guidelines pooled it, 235 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Guideline
  8. Does Messaging for Reducing Breast Cancer Overscreening in Older Women Have Differential Responses among Medical Minimizers and Maximizers?Medical decision making : an international journal of the Society for Medical Decision Making · 2026
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Observational
  17. Article
  18. Article
  19. Social Drivers of Guideline-Discordant Breast Cancer Screening by Age and Mortality Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Louise C WalterUniversity of California, San Francisco2San Francisco VA Medical Center, San Francisco, California.
Mara A SchonbergDivision of General Medicine and Primary Care, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Harvard University · USUniversity of California, San Francisco · US

Funding

Prostate-Specific Antigen Practices and Outcomes in the ElderlyR01CA134425 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WALTER, LOUISE C. · 2009 to 2013
$1.7M
Midcareer Mentoring Award for Patient-Oriented Research in AgingK24AG041180 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WALTER, LOUISE C. · 2011 to 2016
$909k
Benefits and Burdens of Screening Oldest-old Women: the Case of MammographyK23AG028584 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SCHONBERG, MARA A · 2007 to 2008
$313k
NCI NIH HHS R01 CA134425NIA NIH HHS K23 AG028584NIA NIH HHS K23AG028584NIA NIH HHS K24 AG041180NIA NIH HHS K24AG041180
6 · The paper itself

Abstract

importanceGuidelines recommend individualizing screening mammography decisions for women aged 75 years and older. However, little pragmatic guidance is available to help counsel patients.

objectiveTo provide an evidence-based approach for individualizing decision-making about screening mammography in older women. EVIDENCE ACQUISITION: We searched PubMed for English-language studies in peer-reviewed journals published from January 1, 1990, to February 1, 2014, to identify risk factors for late-life breast cancer in women aged 65 years and older and to quantify the benefits and harms of screening mammography for women aged 75 years and older.

findingsAge is the major risk factor for developing and dying from breast cancer. Breast cancer risk factors that reflect hormonal exposures in the distant past, such as age at first birth or age at menarche, are less predictive of late-life breast cancer than factors indicating recent hormonal exposures such as high bone mass or obesity. Randomized trials of the benefits of screening mammography did not include women older than 74 years. Thus it is not known if screening mammography benefits older women. Observational studies favor extending screening mammography to older women who have a life expectancy of more than 10 years. Modeling studies estimate 2 fewer breast cancer deaths/1000 women who in their 70s continue biennial screening for 10 years instead of stopping screening at age 69. Potential harms of continued screening over 10 years include false-positive mammograms in approximately 200/1000 women screened and overdiagnosis (ie, finding breast cancer that would not have clinically surfaced otherwise) in approximately 13/1000 women screened. Providing information about life expectancy along with potential benefits and harms of screening may help older women's decision-making about screening mammography. CONCLUSIONS AND RELEVANCE: For women with less than a 10-year life expectancy, recommendations to stop screening mammography should emphasize increased potential harms from screening and highlight health promotion measures likely to be beneficial over the short term. For women with a life expectancy of more than 10 years, deciding whether potential benefits of screening outweigh harms becomes a value judgment for patients, requiring a realistic understanding of screening outcomes.

Indexed as

Decision MakingEarly Detection of CancerMammographyAgedAged, 80 and overAge FactorsBreast NeoplasmsFalse Positive ReactionsFemaleHumansLife ExpectancyRisk Factors

Identifiers

PMID24691609
PMCPMC4391705
OpenAlexW2112090688

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.